Replies to post #3650 on Conversion Labs Inc fka CVLB

[jefra1965]

$LFMD. From another board

I called the company and it appears this quarter continues the strong growth! It even appears that the second derivative of growth is increasing which means that the growth rate itself is increasing. The contribution margin which is the company’s gross margin less variable costs continues to increase dramatically as the mix shifts to subscription based sales and more prescription sales from Rex. The company is launching many new and highly profitable products over the next 3 weeks. In addition this Conceirge launch which differentiates the company from all telemedicine companies and puts it in a class of its own has not been valued in the stock. This company is in its own growth cycle and should not be traded like the other telemed cos. They are growing faster and with independent sales dynamics. Plus they will be spinning out or selling a non strategic division with over $25/ shr by itself!